1-Bromo-3-Fluoro-5-Nitrobenzene Grading for Kinase Inhibitor Synthesis
HPLC Purity Grading for 1-Bromo-3-fluoro-5-nitrobenzene: ≥97% vs. ≥99.5% in Kinase Inhibitor Intermediates
When sourcing 1-Bromo-3-fluoro-5-nitrobenzene (CAS 7087-65-2) for kinase inhibitor synthesis, procurement managers must navigate a critical decision: selecting between ≥97% and ≥99.5% HPLC purity grades. This fluorinated aromatic intermediate serves as a pivotal aryl bromide building block in constructing small molecule RTK inhibitors, where even minor impurities can cascade into significant downstream failures. The ≥97% grade, often termed "technical grade," may suffice for early-stage research or non-GMP steps, but its 3% impurity window frequently harbors problematic halogenated byproducts. In contrast, the ≥99.5% grade, a true pharmaceutical grade material, minimizes these risks, ensuring consistent reactivity and reducing purification burdens. Our field experience shows that the cost differential—typically 20-30%—is quickly offset by avoided rework in later synthetic stages. For a seamless drop-in replacement to your current supplier, our high-purity 1-Bromo-3-fluoro-5-nitrobenzene matches identical technical parameters while offering cost-efficiency and reliable supply.
Critical COA Parameters: Trace Dibromo and Defluorinated Impurity Thresholds Causing Peak Tailing
A batch-specific Certificate of Analysis (COA) reveals more than a single purity number. Two non-standard parameters demand scrutiny: trace dibromo impurities (e.g., 1,3-dibromo-5-nitrobenzene) and defluorinated species (e.g., 3-bromo-5-nitroaniline). In our hands, dibromo content above 0.2% by HPLC area% causes pronounced peak tailing on standard C18 columns, complicating accurate purity assessment. This tailing often masks co-eluting impurities, leading to overestimated purity. Defluorinated impurities, even at 0.1%, can act as chain terminators in cross-coupling reactions, drastically reducing yields. We've observed that when stored improperly, moisture-induced degradation can elevate these impurities—a topic explored in our article on bulk storage and moisture prevention. For GMP-stage synthesis, we recommend a COA specification of ≤0.15% for any single unknown impurity and ≤0.5% total impurities, with explicit limits for dibromo and defluorinated analogs. Please refer to the batch-specific COA for exact values.
| Parameter | ≥97% Grade (Typical) | ≥99.5% Grade (Typical) |
|---|---|---|
| HPLC Purity (area%) | 97.5% | 99.7% |
| Dibromo Impurity | 0.8% | 0.1% |
| Defluorinated Impurity | 0.5% | 0.05% |
| Peak Tailing Factor (USP) | 1.8 | 1.2 |
| Appearance | Pale yellow solid | White to off-white solid |
Downstream Recrystallization Failures: How Sub-0.5% Halogenated Byproducts Impact API Crystallization
In kinase inhibitor API synthesis, the final crystallization step is exquisitely sensitive to trace halogenated byproducts. We've investigated cases where a 0.3% impurity of 3-bromo-5-fluoronitrobenzene isomer (a positional isomer) in the nitrobenzene derivative intermediate led to API batches failing polymorphic form specifications. The impurity incorporates into the crystal lattice, altering nucleation kinetics and resulting in inconsistent particle size distribution. This is particularly critical for compounds targeting RTK pathways, where bioavailability hinges on crystalline form. Our impurity profiling studies, detailed in trace impurity control for API color compliance, demonstrate that maintaining individual halogenated byproducts below 0.1% is essential for reproducible crystallization. As a global manufacturer, we control these through rigorous manufacturing process optimization, including low-temperature bromination and fractional distillation, ensuring our industrial purity material performs as a true drop-in replacement.
Bulk Packaging and Supply Chain Reliability for 1-Bromo-3-fluoro-5-nitrobenzene: IBC and 210L Drum Logistics
For kilo-lab to pilot-scale campaigns, packaging integrity directly impacts material quality. We supply 1-Bromo-3-fluoro-5-nitrobenzene in 210L steel drums with PTFE-lined seals, or 1000L IBCs for bulk orders, both under nitrogen blanket. A field note: this compound exhibits a slight viscosity increase below 5°C, which can slow drum emptying. Pre-warming to 15-20°C restores flowability without degradation. Our logistics network ensures door-to-door delivery with full traceability, avoiding the moisture ingress that accelerates NAS degradation. For custom synthesis or bulk price inquiries, our supply chain is structured to handle multi-ton demands with consistent lot-to-lot quality.
Frequently Asked Questions
What are small molecule RTK inhibitors?
Small molecule receptor tyrosine kinase (RTK) inhibitors are a class of targeted cancer therapies that block aberrant signaling pathways by binding to the intracellular kinase domain. Their synthesis often relies on halogenated nitrobenzene intermediates like 1-Bromo-3-fluoro-5-nitrobenzene for sequential cross-coupling reactions to build the core scaffold.
How can I verify trace halogenated byproducts in my COA?
Request a COA with HPLC method details, including column type, gradient, and detection wavelength (typically 254 nm). Ensure the method resolves dibromo and defluorinated impurities with resolution >2.0. For critical applications, ask for spiked impurity studies or LC-MS confirmation of peak identity.
What impurity profile is acceptable for GMP-stage synthesis?
For GMP intermediates, individual unspecified impurities should be ≤0.10%, with total impurities ≤0.5%. Specific limits for dibromo and defluorinated species should be ≤0.15% each. Always align with ICH Q3A guidelines and your API's final specification.
How do assay variations impact final API crystallization yields?
Even a 1% assay drop due to impurities can reduce crystallization yield by 5-10% because impurities disrupt crystal lattice formation. Consistent assay >99% ensures predictable supersaturation curves and polymorph control, critical for kinase inhibitors with stringent bioavailability requirements.
Sourcing and Technical Support
Selecting the right grade of 1-Bromo-3-fluoro-5-nitrobenzene is a strategic decision that balances upfront cost against downstream process robustness. Our team provides comprehensive analytical support, including impurity spiking studies and forced degradation data, to qualify our material for your specific synthesis route. We understand the nuances of 3-Bromo-5-fluoronitrobenzene handling and offer tailored logistics solutions. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.